George Kafatos1, Victoria Banks1, Peter Burdon2, David Neasham1, Kimberly A Lowe3, Caroline Anger4, Fil Manuguid4, Jörg Trojan5. 1. Center for Observational Research, Amgen Ltd., 1 Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DK, UK. 2. Medical Affairs, Amgen (Europe) GmbH, Suurstoffi 22, Postfach 94, Rotkreuz 6343, Switzerland. 3. Center for Observational Research, Amgen Inc., One Amgen Center Drive, MS D2262, Thousand Oaks, CA 91320, USA. 4. IQVIA Real-World & Analytics solutions, 210 Pentonville Road, London, N1 9JY, UK. 5. Medizinische Klinik 1, Universitätsklinikum Frankfurt, Goethe-Universität, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany.
Abstract
Background: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often administered to patients with RAS wild-type mCRC and those with left-sided tumors, while anti-VEGF mAbs were preferred in RAS mutant and right-sided tumors. Adopted treatment strategies differed between countries, largely due to reimbursement. Conclusion: Biomarker status and primary tumor location steered treatment decisions in first line. Adopted treatment strategies differed between participating countries.
Background: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often administered to patients with RAS wild-type mCRC and those with left-sided tumors, while anti-VEGF mAbs were preferred in RAS mutant and right-sided tumors. Adopted treatment strategies differed between countries, largely due to reimbursement. Conclusion: Biomarker status and primary tumor location steered treatment decisions in first line. Adopted treatment strategies differed between participating countries.
Authors: Alexander R Siebenhüner; Giorgia Lo Presti; Daniel Helbling; Petr Szturz; Christoforos Astaras; Yannick Buccella; Sara De Dosso Journal: Curr Oncol Date: 2022-08-06 Impact factor: 3.109